Company news
Sumitomo Pharma Co.ltd. (TSE:4506) news
Sumitomo Pharma Co.ltd. news releases on 6ix. Latest, Aug 28, 2026: Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income)…
Press releases & updates
Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements
August 28, 2026
Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)
August 11, 2026
Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”
August 6, 2026
Regarding a Report Concerning Sumitomo Pharma
August 4, 2026
Presentation Material (Conference on Q1 FY2026 Financial Results)
July 31, 2026
Matters Concerning Controlling Shareholders, Etc.
June 25, 2026
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
June 1, 2026
Sumitomo Pharma : Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change
May 31, 2026
New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
May 18, 2026
Sumitomo Pharma : May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）
May 15, 2026
Sumitomo Pharma : Posted Conference on FY2025 Financial Results
May 15, 2026
Sumitomo Pharma : May 13, 2026 Conference on FY2025 Financial Results（PDF/1,054KB）
May 13, 2026
Sumitomo Pharma : Presentation Material (Conference on FY2025 Financial Results )
May 13, 2026
Sumitomo Pharma : Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia
March 30, 2026
Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
March 23, 2026
Sumitomo Pharma : Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan
March 5, 2026
Sumitomo Pharma : May. 02, 2026 Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma - transcript（PDF/6,280KB）
March 4, 2026
Sumitomo Pharma : May. 03, 2026 Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma -（PDF/3,386KB）
March 2, 2026
Sumitomo Pharma : Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -)
March 2, 2026
Sumitomo Pharma : Announces Revisions to Its Financial Forecasts
March 2, 2026
Sumitomo Pharma : Announces Boost 2028 - Accelerating Strong Sumitomo Pharma
March 2, 2026
Sumitomo Pharma : Announcement of Filing of Shelf Registration Statement for Issuance of New Shares
March 2, 2026
Sumitomo Pharma : Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)
February 26, 2026
Sumitomo Pharma : Feb. 17, 2026 R&D Meeting transcript（PDF/5,926KB）
February 19, 2026
Sumitomo Pharma : Feb. 17, 2026 R&D Meeting（PDF/2,493KB）
February 16, 2026
Sumitomo Pharma : Jan. 30, 2026 Conference on Q3 FY2025 Financial Results transcript（PDF/3,079KB）
February 2, 2026
Sumitomo Pharma : Posted Conference on Q3 FY2025 Financial Results
February 2, 2026
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
December 8, 2025
Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
November 3, 2025
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
October 7, 2025
Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
July 30, 2025
Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA®
June 30, 2025
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
June 19, 2025